This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Milliken, E. L. Articles by Keri, R. A. Search for Related Content PubMed PubMed Citation Articles by Milliken, E. L. Articles by Keri, R. A.

Ovarian Hyperstimulation by LH Leads to Mammary Gland Hyperplasia and Cancer Predisposition in Transgenic Mice

Departments of Pharmacology (E.L.M., R.K.A., M.D.L., A.B., R.A.K.) and Pathology (F.W.A.-K.), Case Western Reserve University; and Department of Pathology (F.W.A.-K.), University Hospitals of Cleveland, Cleveland, Ohio 44106

Address all correspondence and requests for reprints to: Ruth A. Keri, Ph.D., Assistant Professor, Department of Pharmacology, Case Western Reserve University, School of Medicine, 2109 Adelbert Road, Cleveland, Ohio 44106-4965. E-mail: rak5{at}po.cwru.edu.

Many risk factors for breast cancer are associated with hormonally regulated events. Although numerous mouse models of mammary cancer exist, few address the roles of hormones in spontaneous tumor formation. Here we report that transgenic mice that overexpress LH, resulting in ovarian hyperstimulation, undergo precocious mammary gland development. A significant increase in proliferation leads to ovary-dependent mammary gland hyperplasia. Transgenic glands morphologically mimic those of wild-type pregnant mice and expression levels of multiple milk protein genes are comparable with what is observed at d 14 of pregnancy. In addition to sustained hyperplasia, spontaneous mammary tumors were observed with a mean latency of 41 wk, indicating that chronic hormonal stimulation causes mammary cancer. Although hormonally induced, these tumors lack expression of progesterone receptor, suggesting that following initiating events, the tumors may become hormone independent. This mouse model likely holds great potential as a tool for discovery of hormone-mediated mechanisms of breast cancer and identification of future targets for breast cancer prevention and treatment.

This article has been cited by other articles:

				D. Piersma, E. M. J. J. Berns, M. Verhoef-Post, A. G. Uitterlinden, I. Braakman, H. A. P. Pols, and A. P. N. Themmen A Common Polymorphism Renders the Luteinizing Hormone Receptor Protein More Active by Improving Signal Peptide Function and Predicts Adverse Outcome in Breast Cancer Patients J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1470 - 1476. [Abstract] [Full Text] [PDF]

				K. A. B. Knostman, J.-Y. Cho, K.-Y. Ryu, X. Lin, J. A. McCubrey, T. Hla, C. H. Liu, E. Di Carlo, R. Keri, M. Zhang, et al. Signaling through 3',5'-Cyclic Adenosine Monophosphate and Phosphoinositide-3 Kinase Induces Sodium/Iodide Symporter Expression in Breast Cancer J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5196 - 5203. [Abstract] [Full Text] [PDF]

				H. P. Mohammad, D. D. Seachrist, C. C. Quirk, and J. H. Nilson Reexpression of p8 Contributes to Tumorigenic Properties of Pituitary Cells and Appears in a Subset of Prolactinomas in Transgenic Mice that Hypersecrete Luteinizing Hormone Mol. Endocrinol., October 1, 2004; 18(10): 2583 - 2593. [Abstract] [Full Text] [PDF]

				J. S. Jorgensen, C. C. Quirk, and J. H. Nilson Multiple and Overlapping Combinatorial Codes Orchestrate Hormonal Responsiveness and Dictate Cell-Specific Expression of the Genes Encoding Luteinizing Hormone Endocr. Rev., August 1, 2004; 25(4): 521 - 542. [Abstract] [Full Text] [PDF]

				H. P. Mohammad, R. A. Abbud, A. F. Parlow, J. S. Lewin, and J. H. Nilson Targeted Overexpression of Luteinizing Hormone Causes Ovary-Dependent Functional Adenomas Restricted to Cells of the Pit-1 Lineage Endocrinology, October 1, 2003; 144(10): 4626 - 4636. [Abstract] [Full Text] [PDF]

				M. M. Matzuk, F. J. DeMayo, L. A. Hadsell, and T. R. Kumar Overexpression of Human Chorionic Gonadotropin Causes Multiple Reproductive Defects in Transgenic Mice Biol Reprod, July 1, 2003; 69(1): 338 - 346. [Abstract] [Full Text] [PDF]

				B. L. Powell, D. Piersma, M. E. Kevenaar, I. L. van Staveren, A. P. N. Themmen, B. J. Iacopetta, and E. M. J. J. Berns Luteinizing Hormone Signaling and Breast Cancer: Polymorphisms and Age of Onset J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1653 - 1657. [Abstract] [Full Text] [PDF]

				R. J. Mann, R. A. Keri, and J. H. Nilson Consequences of Elevated Luteinizing Hormone on Diverse Physiological Systems: Use of the LH{beta}CTP Transgenic Mouse as a Model of Ovarian Hyperstimulation-induced Pathophysiology Recent Prog. Horm. Res., January 1, 2003; 58(1): 343 - 375. [Abstract] [Full Text] [PDF]